1998
Serotonin Transporter Protein Gene Polymorphism and Personality Measures in African American and European American Subjects
Gelernter J, Kranzler H, Coccaro EF, Siever LJ, New AS. Serotonin Transporter Protein Gene Polymorphism and Personality Measures in African American and European American Subjects. American Journal Of Psychiatry 1998, 155: 1332-1338. PMID: 9766763, DOI: 10.1176/ajp.155.10.1332.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack PeopleCarrier ProteinsFemaleGene FrequencyGenotypeHumansIntronsMaleMembrane GlycoproteinsMembrane Transport ProteinsNerve Tissue ProteinsPersonalityPersonality DisordersPolymorphism, GeneticPromoter Regions, GeneticSerotoninSerotonin Plasma Membrane Transport ProteinsSubstance-Related DisordersWhite PeopleConceptsOverall negative findingsSLC6A4 promoter polymorphismNormal comparison subjectsPsychiatric diagnostic groupsProtein gene polymorphismsAmerican subjectsSynaptic inactivationComparison subjectsPromoter polymorphismPsychiatric diagnosisEuropean-American subjectsGene polymorphismsNeuroticism scoresDiagnostic groupsDemographic featuresNegative findingsHarm avoidanceNeurotransmitter serotoninSubstance dependenceSerotonin transporterPersonality disorderSLC6A4 polymorphismsDemographic factorsPresent findingsPromoter region
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity